Neurological Sciences (Neurol Sci)

Publisher: Società italiana di neurologia; Società italiana di neurofisiologia clinica, Springer Verlag

Journal description

Neurological Sciences is intended to provide a medium for the communication of results and ideas in the field of neuroscience. The journal welcomes contributions in both the basic and clinical aspects of the neurosciences. The official language of the journal is English. Reports are published in the form of original articles short communications editorials reviews and case reports. Original articles present the results of experimental or clinical studies in the neurosciences while short communications are succinct reports permitting the rapid publication of novel results. Original contributions may be submitted for the special sections History of Neurology Health Care and Neurological Digressions - a forum for cultural topics related to the neurosciences. The journal also publishes correspondence book reviews meeting reports and announcements and is available for the publication of supplernents and abstracts of scientific meetings: details may be obtained from the Editor-in-Chief or the publisher.

Current impact factor: 1.45

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 1.447
2013 Impact Factor 1.495
2012 Impact Factor 1.412
2011 Impact Factor 1.315
2010 Impact Factor 1.22
2009 Impact Factor 1.12
2008 Impact Factor 1.435
2007 Impact Factor 1.006
2006 Impact Factor 0.894
2005 Impact Factor 0.779
2004 Impact Factor 1.059
2003 Impact Factor 0.989
2002 Impact Factor 0.907
2001 Impact Factor 0.38

Impact factor over time

Impact factor

Additional details

5-year impact 1.34
Cited half-life 4.70
Immediacy index 0.37
Eigenfactor 0.01
Article influence 0.37
Website Neurological Sciences website
Other titles Neurological sciences (Online), Neurol sci, Italian journal of neurological sciences
ISSN 1590-3478
OCLC 45587272
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Springer Verlag

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Author's pre-print on pre-print servers such as
    • Author's post-print on author's personal website immediately
    • Author's post-print on any open access repository after 12 months after publication
    • Publisher's version/PDF cannot be used
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany link to published version (see policy)
    • Articles in some journals can be made Open Access on payment of additional charge
  • Classification

Publications in this journal

  • No preview · Article · Mar 2016 · Neurological Sciences

  • No preview · Article · Sep 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alleles of IL-17A and IL-17F genes were reported to be associated with many inflammatory and autoimmune disorders in Asian patients. Serum level and mRNA of IL-17A in peripheral blood mononuclear cells were reported to be significantly higher in MG patients than in healthy controls. In experimental autoimmune myasthenia gravis (EAMG) animals, IL-17 may have effects on the severity of MG. This study investigated the association between four SNPs of IL-17A and IL-17F gene (rs8193036, rs2275913 and rs3748067 in IL-17A; rs763780 in IL-17F) and MG in Chinese patients. The allele frequencies were compared between 480 MG patients and 487 healthy controls, between each MG subgroup and the control group, and between each pairs of MG subgroups. Subgroups were specified by clinical features (onset age, gender, thymoma, AChRAb and muscle involvement at onset) and maximal severity during the follow-up. No associations were found between the four SNPs of IL-17A and IL-17F gene and MG in Chinese patients.
    No preview · Article · Sep 2015 · Neurological Sciences

  • No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: Orthostatic hypotension (OH), a proxy for sympathetic adrenergic failure, is the most incapacitating sign of autonomic failure. Orthostatic dizziness (OD) is known to be the most common symptom of OH. However, recent studies have demonstrated that 30-39 % of patients with OH experienced rotatory vertigo during upright posture (i.e., orthostatic vertigo, OV), which challenges the dogma that OH induces dizziness and not vertigo. A recent population-based study on spontaneously occurring OD across a wide age range showed that the one-year and lifetime prevalence of OD was 10.9 and 12.5 %, respectively. Approximately 83 % of patients with OD had at least one abnormal autonomic function test result. So far, 11 subtypes of OD have been proposed according to the pattern of autonomic dysfunction, and generalized autonomic failure of sympathetic adrenergic and parasympathetic cardiovagal functions was the most common type. Four different patterns of OH, such as classic, delayed, early, and transient type have been found in patients with OD. The head-up tilt test and Valsalva maneuver should be performed for a comprehensive evaluation of sympathetic adrenergic failure in patients with OD/OV. This review summarizes current advances in OH presenting OD/OV, with a particular focus on the autonomic dysfunction associated with OD.
    No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: Elderly patients represent an important subgroup in primary central nervous system lymphoma (PCNSL) that accounts for approximately half the cases. Furthermore age represents one of the heaviest prognostic factors and in some cases it has more effect on survival than therapies. We performed a retrospective analysis to assess the toxicity and the efficacy of high-dose methotrexate (HDMTX) chemotherapy in a PCNSL population older than 70 years. Seventeen consecutive immunocompetent patients older than 70 years, with histologically confirmed PCNSL, without systemic involvement, treated with HDMTX at our institution between May 2005 and April 2013, were retrospectively evaluated. Main outcome measures were acute toxicity and tumour response. No evidence of haematological toxicity was recorded in 47 % of patients and no deaths related to toxicity grade were reported. Patients achieved a partial response after 3 cycles of chemotherapy in 53 % of cases. The median overall survival (m-OS) from diagnosis was 20.9 months (range 5.2-34 months), with OS-12 of 58.8 % and an OS-24 of 45.4 %. Since there is no standard of care in the treatment of PCNSL in elderly population, it should be taken into account that elderly patients not always can be considered "fragile" and the general tendency to less treat to avoid severe toxicity should not be the rule.
    No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify any structural differences in macular choroidal thickness in migraine patients and compare them with that of control subjects by using spectral domain optic coherence tomography (SD-OCT). In this prospective study, choroidal thicknesses of 32 migraine patients during migraine attack-free period and 32 age- and sex-matched healthy subjects were measured using SD-OCT. All patients underwent a complete ophthalmic examination before the measurements. The migraine patients were classified into the migraine with aura group or the migraine without aura group. Migraine severity was assessed by visual analog scale (VAS), migraine disability questionnaire (Migraine Disability Assessment Score (MIDAS), and Wong-Baker faces pain rating scale. Thirty eyes of 32 subjects (31 female and 1 male) in the migraine group and 32 eyes of 32 subjects (31 female and 1 male) in control group were evaluated. In the study group, 16 patients suffered migraine without aura (MWA) and 16 patients were diagnosed as migraine with aura (MA). The mean subfoveal choroidal thickness (SFCT) was 353.3 ± 66.5 μm in the control group versus 304.3 ± 72.9 μm and 276.1 ± 61.4 μm in MWA and MA groups, respectively. The difference in SFCT between the migraine patients and the controls was significant (p < 0.001). Additionally, a moderate correlation was found between SFCT and the VAS score and W baker score (r = 0.48, p = 0.008 and r = 0.43, p = 0.02, respectively). The choroidal thickness was found to decrease significantly not only in migraine patients with aura but also in those without aura during the attack-free period.
    No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study was aimed to explore the molecular mechanism of Parkinson's disease (PD) development and discover underlying pathways and genes associated with PD. The microarray data of GSE22491 containing 10 samples from PD patients and 8 samples from healthy controls (HC) were downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were identified by paired t-test. Then the DEGs were performed cluster and principal component analyses followed by Gene Ontology (GO) and pathway enrichment analyses and protein-protein interaction (PPI) network construction. Total 176 up-regulated DEGs and 49 down-regulated DEGs were identified. Totally, 39 GO terms and 72 pathways were closely related to PD. Pathway of neuronal system was enriched by 10 DEGs such as synapsin I (SYN1), glutamate receptor, ionotropic, N-methyl-D-aspartate 1 (GRIN1) and GRIN2D. In the PPI networks, 18 hub genes were obtained, such as GRIN2D and discs, large (Drosophila) homolog-associated protein 3 (DLGAP3). The pathway of neuronal system and its enriched DEGs may play important roles in PD progression. The DEGs such as SYN1, GRIN1, GRIN2D and DLGAP3 may become promising candidate genes for PD.
    No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although some studies have reported the associations between specific metal element intake and risk of Parkinson's disease (PD), the associations between specific metal element intake such as iron intake and PD are still conflicted. We aimed to determine whether intake of iron, zinc, and copper increases/decreases the risk of PD. PubMed, Embase, Web of Knowledge, and Google Scholar were searched. We pooled the multivariate-adjusted relative risks (RRs) or odds ratios using random effects. Study quality was evaluated by the Newcastle-Ottawa Scale. Five studies including 126,507 individuals remained for inclusion, pooled RRs of Parkinson's disease for moderate dietary iron intake was 1.08 (95 % CI 0.61-1.93, P = 0.787), and for high dietary iron intake was (1.03, 95 % CI 0.83-1.30, P = 0.766), respectively. The pooled RRs of Parkinson's disease for the highest compared with the lowest dietary iron intake were 1.47 (95 % CI 1.17-1.85, P = 0.001) in western population and in males (RR = 1.43, 95 % CI 1.01-2.01, P = 0.041). The pooled RRs of Parkinson's disease for moderate or high intake of zinc, and copper were not statistically different (P > 0.05). PD increased by 18 % (RR 1.18, 95 % CI 1.02-1.37) for western population by every 10-mg/day increment in iron intake. Higher iron intake appears to be not associated with overall PD risk, but may be associated with risk of PD in western population. Sex may be a factor influencing PD risk for higher iron intake. However, further studies are still needed to confirm the sex-selective effects.
    No preview · Article · Aug 2015 · Neurological Sciences

  • No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to determine the safety and effectiveness of cerebellar arteriovenous malformations (AVMs) embolization and find out the suitable methods to manage associated aneurysms. Medical records of all patients between 1997 and 2014 with a diagnosis of cerebellar AVMs were retrospectively reviewed. Univariable and multivariable logistic analysis were used to assess AVMs characteristics to calculate for the risk of hemorrhage. Endovascular treatment was the main treatment measure to manage the AVMs and associated aneurysms. Of 142 patients, 115 (81.0 %) presented with hemorrhage and 42 (29.6 %) with associated aneurysms. A significant association with cerebellar AVMs hemorrhage was found for small size, prenidal aneurysms, and deep venous drainage in the univariable and multivariable analysis. Associated aneurysms were treated firstly in 41 patients except for 1 patient with 2 prenidal and 2 intranidal aneurysms. The special case was dealt with AVMs and 2 intranidal aneurysms first and angiography showed that the 2 prenidal associated aneurysms disappeared with time. Hemorrhage appeared in 13/142 patients (9.2 %) during the follow-up period, none of which was with associated aneurysms. Endovascular treatment can be a feasible way for treating cerebellar AVMs. Intranidal associated aneurysms should be treated first. Prenidal associated aneurysms can be treated later depending on the angioarchitecture of AVMs.
    No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study purpose is to perform a meta-analysis to help resolve the debate of whether the Angiogenin (ANG) K17I variant is associated with amyotrophic lateral sclerosis (ALS) risk in Caucasian. Three literature databases were searched for eligible studies published up to January 8, 2015: PubMed, Embase and Web of Science using the following search terms: amyotrophic lateral sclerosis or ALS and Angiogenin or ANG. Five eligible articles were identified, which reported 6 case-control studies and a total of 2326 cases and 3799 controls. The overall results suggested low frequencies of the K17I variant in Caucasian patients (10/2326, 0.43 %) and controls (6/3799, 0.16 %). There is no difference in the variant frequencies between patients with FALS or SALS (p = 0.069). Analysis of pooled odds ratios (ORs) and 95 % confidence intervals (CIs) revealed that the ANG K17I variant increases the risk for ALS (AT vs. AA: OR 2.65, 95 % CI 1.05-6.66, p = 0.038) and familial ALS (FALS) (AT vs. AA: OR 11.81, 95 % CI 2.11-66.15, p = 0.005) but not for sporadic ALS (SALS) (AT vs. AA: OR 1.63, 95 % CI 0.55-4.82, p = 0.378). The ANG K17I variant is rare in Caucasian patients and controls and increases the risk for ALS and FALS but not for SALS in Caucasian populations. Further well-designed studies with larger samples are needed to validate these results.
    No preview · Article · Aug 2015 · Neurological Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this work is to investigate the efficacy of exogenous melatonin in the treatment of sleep disorders in patients with neurodegenerative disease. We searched Pubmed, the Cochrane Library, and, from inception to July 2015. We included randomized clinical trials (RCTs) that compared melatonin with placebo and that had the primary aim of improving sleep in people with neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). We pooled data with the weighted mean difference in sleep outcomes. To assess heterogeneity in results of individual studies, we used Cochran’s Q statistic and the I 2 statistic. 9 RCTs were included in this research. We found that the treatment with exogenous melatonin has positive effects on sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) in PD patients (MD: 4.20, 95 % CI: 0.92–7.48; P = 0.01), and by changes in PSQI component 4 in AD patients (MD: 0.67, 95 % CI: 0.04–1.30; P = 0.04), but not on objective sleep outcomes in both AD and PD patients. Treatment with melatonin effectively improved the clinical and neurophysiological aspects of rapid eye movement (REM) sleep behavior disorder (RBD), especially elderly individuals with underlying neurodegenerative disorders. This meta-analysis provided some evidence that melatonin improves sleep quality in patients with AD and PD, and melatonin can be considered as a possible sole or add-on therapy in neurodegenerative disorders patients with RBD.
    No preview · Article · Aug 2015 · Neurological Sciences

  • No preview · Article · Aug 2015 · Neurological Sciences